Table 1. Association between Anti-Streptolysin O (ASLO) and anti-PDI Antibodies.
ASLO positive$ | ASLO negative | Odds Ratio (95% CI) | P value | |
Anti-bovine PD I ¶ | ||||
Exploratory sample (Stanford) | 33.8% (65) | 14.7% (245) | 3.0 (1.6, 5.5) | <0.0001 |
Replication (Stanford) | 33.3% (99) | 11.4% (273) | 3.9 (2.2, 6.8) | <0.0001 |
Wisconsin Sleep Cohort | 38.6% (446) | 10.2% (2401) | 4.6 (3.7, 5.8) | <0.0001 |
All samples | 37.2% (610) | 12.2% (2919) | 4.2 (3.5, 5.2) | <0.0001 |
Anti- human PDI # | ||||
Exploratory sample (Stanford) | 8.3% (24) | 7.5% (80) | 1.1 (0.2, 5.8) | 0.92 |
Replication (Stanford) | 5.9% (85) | 3.4% (263) | 1.7 (0.6, 5.4) | 0.32 |
Wisconsin Sleep Cohort | 15.4% (421) | 5.8% (2114) | 3.0 (2.1, 4.1) | <0.0001 |
All samples | 13.6% (530) | 5.6% (2457) | 2.7 (2.0, 3.6) | <0.0001 |
Results are presented as percentages of positive anti-PDI sera (number of all sera in this subgroup).
ASLO positivity defined as ASLO ≥200 for participants ages 6–40 years and ASLO ≥100 for participants older than 40 years, as recommended [40].
Anti-bovine PDI defined as positive if ELISA OD ≥0.5.
Anti-human PDI defined as positive if ELISA OD ≥0.75.